Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCY-078 plus Voriconazole in Invasive Pulmonary Aspergillosis
NCT03672292Phase 2Terminated
- Sponsor
- SCYNEXIS, Inc.
- Start
- Jan 2019
- Primary completion
- Mar 2023
- Modality
- Allosteric Modulators
- Countries
- 5
01
Overview
A Phase 2 trial of ibrexafungerp in Invasive Pulmonary Aspergillosis (IPA), sponsored by SCYNEXIS, Inc.. Started Jan 2019; status: terminated.
02
Drugs
ibrexafungerp
03
Conditions
Invasive Pulmonary Aspergillosis (IPA)
Beyond the preview
Go deeper on NCT03672292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672292.